[Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock.

Rhea-AI Filing Summary

Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock. The options have an exercise price of $1.72 per share and expire on April 27, 2036, giving him a long-term incentive tied to the company’s share price.

According to the vesting schedule, 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months beginning on May 27, 2027. After this grant, Aggarwal holds 400,000 stock options directly under this award.

Insider Trade Summary

Grant/Award: 400,000 shares

Grant/Award 1 txn

Insider Aggarwal Ajay

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	400,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 400,000 contracts (Direct)

Footnotes (1)

1. F1. 100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027

Key Figures

Stock options granted: 400,000 options Exercise price: $1.72 per share Options expiration: April 27, 2036 +3 more

6 metrics

Stock options granted 400,000 options Grant to COO Ajay Aggarwal on April 27, 2026

Exercise price $1.72 per share Exercise price for the 400,000 stock options

Options expiration April 27, 2036 Expiration date of the stock option award

Initial cliff vest 100,000 options Vest on April 27, 2027

Monthly vesting tranche 8,333 options per month Vest monthly for 36 months starting May 27, 2027

Total options after grant 400,000 options Total stock options held under this grant following transaction

Key Terms

Stock Options, exercise price, vesting, Common Stock

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price: "1.7200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100,000 vest on April 27, 2027 and 8,333 vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardiff Oncology (CRDF) disclose about Ajay Aggarwal in this Form 4?

Cardiff Oncology reported that COO Ajay Aggarwal received a grant of 400,000 stock options. These options are compensation-based awards that allow him to buy company common stock at a fixed $1.72 exercise price in the future if he chooses.

How many stock options did Cardiff Oncology (CRDF) grant to its COO?

Ajay Aggarwal was granted 400,000 stock options tied to Cardiff Oncology common stock. This entire award is held directly and represents a derivative position that can become shares if he exercises the options after they vest over time.

What is the exercise price of Ajay Aggarwal’s Cardiff Oncology (CRDF) options?

The stock options granted to Ajay Aggarwal have an exercise price of $1.72 per share. This means he can later purchase Cardiff Oncology common stock at $1.72 for each option that has vested and remains unexpired, regardless of future market prices.

When do Ajay Aggarwal’s Cardiff Oncology (CRDF) stock options vest?

The options vest in stages: 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months starting May 27, 2027. This creates a multi-year vesting schedule that encourages long-term alignment with the company.

When do the Cardiff Oncology (CRDF) stock options granted to the COO expire?

Ajay Aggarwal’s stock options expire on April 27, 2036. After that date, any unexercised options will lapse. The long duration gives him many years in which vested options can potentially be exercised, depending on company performance and his decisions.

Is Ajay Aggarwal buying or selling Cardiff Oncology (CRDF) shares in this Form 4?

This Form 4 reports a grant of stock options, not an open-market stock purchase or sale. The transaction is classified as a grant, award, or other acquisition of derivative securities, providing future rights to acquire common stock upon vesting and exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 06:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aggarwal Ajay

(Last) (First) (Middle)

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.72	04/27/2026		A		400,000		(1)	04/27/2036	Common Stock	400,000	$0	400,000	D

Explanation of Responses:

1. 100,000 vest on April 27, 2027 and 8,333 vest monthly for 36 months beginning on May 27, 2027

	/s/ Ajay Aggawral	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)